HomeCompareABBV vs PAA

ABBV vs PAA: Dividend Comparison 2026

ABBV yields 3.06% · PAA yields 7.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAA wins by $7.57M in total portfolio value
10 years
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →
PAA
PAA
● Live price
7.17%
Share price
$21.72
Annual div
$1.56
5Y div CAGR
57%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.67M
Annual income
$5,895,593.77
Full PAA calculator →

Portfolio growth — ABBV vs PAA

📍 PAA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVPAA
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + PAA cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
PAA pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
PAA
Annual income on $10K today (after 15% tax)
$609.50/yr
After 10yr DRIP, annual income (after tax)
$5,011,254.70/yr
At 15% tax rate, PAA beats the other by $4,990,198.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + PAA for your $10,000?

ABBV: 50%PAA: 50%
100% PAA50/50100% ABBV
Portfolio after 10yr
$3.89M
Annual income
$2,960,182.76/yr
Blended yield
76.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
PAA
Analyst Ratings
1
Strong
23
Buy
16
Hold
2
Sell
Consensus: Buy
Price Target
$21.83
+0.5% upside vs current
Range: $17.00 — $25.00
Altman Z
2.3
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
0
PAA buys
16
PoliticianChamberTickerTypeAmountDate
Virginia Foxx🏢 House$PAA▼ Sell$15,001 - $50,0002023-10-03
Virginia Foxx🏢 House$PAA▲ Buy$15,001 - $50,0002023-03-24
Virginia Foxx🏢 House$PAA▼ Sell$100,001 - $250,0002022-06-23
David P. Joyce🏢 House$PAA▲ Buy$1,001 - $15,0002022-05-19
Virginia Foxx🏢 House$PAA▲ Buy$1,001 - $15,0002022-05-16
Virginia Foxx🏢 House$PAA▲ Buy$1,001 - $15,0002022-02-15
Virginia Foxx🏢 House$PAA▲ Buy$15,001 - $50,0002022-01-21
Mark Dr Green🏢 House$PAA▼ Sell$500,001 - $1,000,0002022-01-06
Mark Dr Green🏢 House$PAA▲ Buy$500,001 - $1,000,0002021-12-29
Virginia Foxx🏢 House$PAA▲ Buy$15,001 - $50,0002021-11-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVPAA
Forward yield3.06%7.17%
Annual dividend / share$6.65$1.56
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%57%
Portfolio after 10y$102.3K$7.67M
Annual income after 10y$24,771.77$5,895,593.77
Total dividends collected$61.0K$7.49M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$256.15$21.83

Year-by-year: ABBV vs PAA ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrPAA PortfolioPAA Income/yrGap
1← crossover$11,550$430.00$11,826$1,125.79$276.00PAA
2$13,472$627.96$14,607$1,953.46$1.1KPAA
3$15,906$926.08$19,170$3,540.40$3.3KPAA
4$19,071$1,382.55$27,329$6,817.52$8.3KPAA
5$23,302$2,095.81$43,503$14,261.03$20.2KPAA
6$29,150$3,237.93$79,858$33,308.95$50.7KPAA
7$37,536$5,121.41$175,164$89,715.94$137.6KPAA
8$50,079$8,338.38$476,169$288,743.98$426.1KPAA
9$69,753$14,065.80$1,661,219$1,151,717.73$1.59MPAA
10$102,337$24,771.77$7,673,098$5,895,593.77$7.57MPAA

ABBV vs PAA: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

PAAStock

Plains All American Pipeline, L.P., through its subsidiaries, engages in the pipeline transportation, terminalling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates in two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and at times on barges or railcars. This segment provides terminalling, storage, and other facilities-related services, as well as merchant activities. As of December 31, 2021, this segment owned and leased 18,300 miles of active crude oil transportation pipelines and gathering systems, as well as an additional 110 miles of pipelines that supports crude oil storage and terminalling facilities; 74 million barrels of commercial crude oil storage capacity; 38 million barrels of active, above-ground tank capacity; four marine facilities; a condensate processing facility; seven crude oil rail terminals and 2,100 crude oil railcars; and 640 trucks and 1,275 trailers. The Natural Gas Liquids segment engages in the natural gas processing, NGL fractionation, storage, transportation, and terminalling activities. As of December 31, 2021, this segment owned and operated four natural gas processing plants; nine fractionation plants; 28 million barrels of NGL storage capacity; approximately 1,620 miles of active NGL transportation pipelines, as well as an additional 55 miles of pipeline that supports NGL storage facilities; 16 NGL rail terminals and approximately 3,900 NGL rail cars; and approximately 220 trailers. The company was founded in 1981 and is headquartered in Houston, Texas. Plains All American Pipeline, L.P. operates as a subsidiary of Plains GP Holdings, L.P.

Full PAA Calculator →
📬

Get this ABBV vs PAA comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.